Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

AbbVie Shows Rising Relative Price Performance; Still Shy Of Key Threshold

AbbVie Shows Rising Relative Price Performance; Still Shy Of Key Threshold

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

HR leaders share how they're putting people first in an ever-changing workplace

HR leaders share how they're putting people first in an ever-changing workplace

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Undervalued Dividend Aristocrats Poised for Explosive Gains in 2025

Hunting for value? These three Dividend Aristocrats look cheap by today's valuations.

AbbVie's Q3 2024 Earnings: What to Expect

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

3 Highest-yielding Dividend Kings for Maximum Income and Stability

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Pharma company funding for patient advocacy groups needs to be transparent

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

3 Dividend Powerhouses, Including One With 7% Yield

3 Dividend Powerhouses, Including One With 7% Yield

By investing in these dividend powerhouses, investors can achieve reliable income, mitigate risk through diversification, and potentially enjoy capital gains.

Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Investors Business Daily

Is AbbVie Stock Outperforming the Nasdaq?

Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review

Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review

The stock market rally had a mixed week, with the Dow Jones hitting a high while Nvidia led a Nasdaq retreat.

Investors Business Daily

3 Defensive Dividend Stocks to Scoop Up Now

3 Defensive Dividend Stocks to Scoop Up Now

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.

3 Safe High-Yield Dividend Stocks to Pounce on Now

3 Safe High-Yield Dividend Stocks to Pounce on Now

In today's volatile market, dividend stocks remain one of the safest choices.

Get all your
news in one place.

100’s of premium titles.
One news app.

Nervous About the Market? 3 Defensive Stock Picks to Consider This August

Explore three defensive stock picks from the consumer staples, healthcare, and utilities sectors that offer stability amid market uncertainty in August.

Best Stocks to Buy for Fed Rate Cuts

Consider these stock and fund picks now that the Federal Reserve's rate-cutting campaign is underway.

Investors Business Daily

13 Stocks Make Investors $200 Billion Richer As The Rest Collapse

The S&P 500 is down a staggering $3.2 trillion in the market implosion since mid-July. But some investors are dodging the pain.

What Are Wall Street Analysts' Target Price for Abbvie Stock?

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Secure Decades of Passive Income: 3 Top Dividend Stocks to Buy Now

These companies have consistently paid and increased their dividends, and they have a growing earnings base to support their future payouts.

Investors Business Daily

AbbVie Is About To Have A New Golden Goose As Humira Sales Continue Slowing

AbbVie stock slipped Thursday despite a second-quarter beat that included strong Skyrizi sales and a boost to 2024 earnings guidance.

3 Highest-Yielding Dividend Kings That Wall Street Loves

A high yield doesn't necessarily translate to a buy. This article bridges the gap by combining high dividend payouts and buy ratings.

Option Volatility And Earnings Report For July 22 - 26

This week we have Tesla (TSLA), Microsoft (MSFT), Alphabet (GOOGL), Exxon Mobil (XOM), Visa (V), Abbvie (ABBV) and Chipotle Mexican Grill (CMG) all set to report.

AbbVie Earnings Preview: What to Expect

AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.

Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

Down 14% from All-Time Highs, is This Dividend King a Buy on the Dip?

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Organisations

US Federal Reserve

the Federal Reserve

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

265,375 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play